Akebia Therapeutics
AKBA · NASDAQ
$0.6181−$0.062 (−9.12%)TodayMarket closed ·
Prev close $0.6801
EPS: actual vs estimate
Beat the estimate in 4 of the last 8 quarters, by 99.6% on average
Reported EPS
Estimated EPS
| Quarter | Estimate | Reported | Surprise |
|---|---|---|---|
| Q2 FY26 | -$0.0449 | -$0.03 | +33.2% |
| Q1 FY26 | -$0.0286 | -$0.03 | −4.9% |
| Q4 FY25 | -$0.0255 | -$0.05 | −96.1% |
| Q3 FY25 | -$0.0179 | $0.00 | +100.0% |
| Q2 FY25 | -$0.0204 | $0.00 | +100.0% |
| Q1 FY25 | -$0.0459 | $0.03 | +165.4% |
| Q4 FY24 | -$0.0816 | -$0.10 | −22.5% |
| Q3 FY24 | -$0.0646 | -$0.10 | −54.8% |
Earnings calls
- AKBA - Earnings call Q2 2026
- AKBA - Earnings call Q1 2026
- Special Call - Akebia Therapeutics, Inc.
- Leerink Global Healthcare Conference 2026
- AKBA - Earnings call Q4 2025
- Guggenheim Securities Emerging Outlook: Biotech Summit 2026
- AKBA - Earnings call Q3 2025
- Wells Fargo 20th Annual Healthcare Conference 2025
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.